NO993646D0 - Thiazole benzenesulfonamides as <beta> 3 agonists for the treatment of diabetes and obesity - Google Patents
Thiazole benzenesulfonamides as <beta> 3 agonists for the treatment of diabetes and obesityInfo
- Publication number
- NO993646D0 NO993646D0 NO993646A NO993646A NO993646D0 NO 993646 D0 NO993646 D0 NO 993646D0 NO 993646 A NO993646 A NO 993646A NO 993646 A NO993646 A NO 993646A NO 993646 D0 NO993646 D0 NO 993646D0
- Authority
- NO
- Norway
- Prior art keywords
- obesity
- agonists
- diabetes
- beta
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3676097P | 1997-01-28 | 1997-01-28 | |
GBGB9705041.3A GB9705041D0 (en) | 1997-03-12 | 1997-03-12 | Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity |
PCT/US1998/001317 WO1998032753A1 (en) | 1997-01-28 | 1998-01-23 | THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
Publications (2)
Publication Number | Publication Date |
---|---|
NO993646D0 true NO993646D0 (en) | 1999-07-27 |
NO993646L NO993646L (en) | 1999-09-27 |
Family
ID=26311166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO993646A NO993646L (en) | 1997-01-28 | 1999-07-27 | Thiazolebenzenesulfonamides as <beta> 3 agonists for the treatment of diabetes and obesity |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP0968209A1 (en) |
JP (1) | JP2001509166A (en) |
KR (1) | KR20000070568A (en) |
CN (1) | CN1251099A (en) |
AR (1) | AR011092A1 (en) |
AU (1) | AU728812B2 (en) |
BG (1) | BG103686A (en) |
BR (1) | BR9807096A (en) |
CA (1) | CA2278739A1 (en) |
EA (1) | EA199900692A1 (en) |
EE (1) | EE9900328A (en) |
HR (1) | HRP980044A2 (en) |
HU (1) | HUP0002053A3 (en) |
ID (1) | ID22273A (en) |
IL (1) | IL131130A0 (en) |
IS (1) | IS5131A (en) |
NO (1) | NO993646L (en) |
PE (1) | PE52299A1 (en) |
PL (1) | PL334833A1 (en) |
SK (1) | SK100099A3 (en) |
TR (1) | TR199902442T2 (en) |
WO (1) | WO1998032753A1 (en) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19824175A1 (en) * | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino azole compounds |
PT1741445E (en) | 2000-01-21 | 2013-11-11 | Novartis Ag | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
US20030018061A1 (en) * | 2000-01-28 | 2003-01-23 | Kohei Ogawa | Novel remedies with the use of beta 3 agonist |
PT1138685E (en) | 2000-03-31 | 2004-08-31 | Pfizer Prod Inc | PROCESS FOR THE PREPARATION OF REPLACED PYRIDINES |
KR20030016396A (en) | 2000-07-13 | 2003-02-26 | 일라이 릴리 앤드 캄파니 | Beta3 adrenergic agonists |
US6410734B1 (en) | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
US6498170B2 (en) | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
US6369232B1 (en) * | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
US6825220B2 (en) | 2000-11-10 | 2004-11-30 | Eli Lilly And Company | 3-Substituted oxindole β 3 agonists |
DE60139639D1 (en) | 2000-12-08 | 2009-10-01 | Takeda Pharmaceutical | SUBSTITUTED THIAZONE DERIVATIVES WITH 3-PYRIDYL GROUPS, PROCESS FOR THEIR PREPARATION AND THEIR USE |
AR035605A1 (en) | 2000-12-11 | 2004-06-16 | Bayer Corp | DERIVATIVES OF AMINOMETIL CHROMANO DI-SUBSTITUTES, A METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3-ADRENE-RECEPTORS AGONISTS |
AR035858A1 (en) | 2001-04-23 | 2004-07-21 | Bayer Corp | CHROME DERIVATIVES 2,6-SUBSTITUTES, PHARMACEUTICAL COMPOSITIONS, USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3 ADRENORRECEPTING AGONISTS |
ATE316088T1 (en) * | 2001-06-22 | 2006-02-15 | Merck & Co Inc | TYROSINE KINASE INHIBITORS |
WO2003016307A1 (en) | 2001-08-14 | 2003-02-27 | Eli Lilly And Company | β3 ADRENERGIC AGONISTS |
US6911463B2 (en) | 2001-08-14 | 2005-06-28 | Eli Lilly And Company | 3-substituted oxindole β-3 agonists |
EP1435951B1 (en) * | 2001-10-12 | 2006-01-18 | Bayer Pharmaceuticals Corporation | Phenyl substituted 5-membered nitrogen containing heterocycles for the tretment of obesity |
JP2005514366A (en) | 2001-11-20 | 2005-05-19 | イーライ・リリー・アンド・カンパニー | 3-Substituted oxindole β3 agonist |
US7071208B2 (en) | 2001-11-20 | 2006-07-04 | Eli Lilly And Company | β3 Adrenergic agonists |
US7009060B2 (en) | 2002-01-11 | 2006-03-07 | Eli Lilly And Company | 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists |
US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | Method of treating men with metabolic and anthropometric disorders |
WO2006132196A1 (en) * | 2005-06-08 | 2006-12-14 | Asahi Kasei Pharma Corporation | NOVEL PHARMACEUTICAL COMPRISING β3 AGONIST |
GEP20135791B (en) | 2005-09-14 | 2013-03-25 | Takeda Pharmaceutical | Use of dipeptidyl peptidase inhibitors |
CN101277960A (en) | 2005-09-29 | 2008-10-01 | 默克公司 | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
EP1937264B1 (en) * | 2005-10-04 | 2011-06-08 | Merck Sharp & Dohme Corp. | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence |
EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
WO2008120653A1 (en) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | Indoledione derivative |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
ES2559319T3 (en) | 2007-06-04 | 2016-02-11 | Synergy Pharmaceuticals Inc. | Guanylate cliclas agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
JP2011522828A (en) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders |
WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
JP5557845B2 (en) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | Novel cyclic benzimidazole derivatives useful as antidiabetic agents |
WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
EP2531501B1 (en) | 2010-02-03 | 2013-11-20 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
EA201690035A1 (en) | 2011-02-25 | 2016-05-31 | Мерк Шарп Энд Домэ Корп. | NEW CYCLIC DERIVATIVES OF AZABENZIMIDAZOLE, USED AS ANTI-DIABETIC AGENTS |
AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
ES2394349B1 (en) | 2012-08-29 | 2013-11-04 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Use of selective beta-3 adrenergic receptor agonists for the treatment of pulmonary hypertension |
WO2014108449A1 (en) | 2013-01-08 | 2014-07-17 | Atrogi Ab | A screening method, a kit, a method of treatment and a compound for use in a method of treatment |
CN104994848A (en) | 2013-02-22 | 2015-10-21 | 默沙东公司 | Antidiabetic bicyclic compounds |
EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
PT3004138T (en) | 2013-06-05 | 2024-06-18 | Bausch Health Ireland Ltd | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0091749A3 (en) * | 1982-04-08 | 1984-12-05 | Beecham Group Plc | Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them |
US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
IL113410A (en) * | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
-
1998
- 1998-01-23 EE EEP199900328A patent/EE9900328A/en unknown
- 1998-01-23 PL PL98334833A patent/PL334833A1/en unknown
- 1998-01-23 CA CA002278739A patent/CA2278739A1/en not_active Abandoned
- 1998-01-23 ID IDW990755A patent/ID22273A/en unknown
- 1998-01-23 BR BR9807096-7A patent/BR9807096A/en not_active IP Right Cessation
- 1998-01-23 WO PCT/US1998/001317 patent/WO1998032753A1/en not_active Application Discontinuation
- 1998-01-23 TR TR1999/02442T patent/TR199902442T2/en unknown
- 1998-01-23 KR KR1019997006814A patent/KR20000070568A/en not_active Application Discontinuation
- 1998-01-23 JP JP53214898A patent/JP2001509166A/en active Pending
- 1998-01-23 HU HU0002053A patent/HUP0002053A3/en unknown
- 1998-01-23 EP EP98903677A patent/EP0968209A1/en not_active Withdrawn
- 1998-01-23 CN CN98803585A patent/CN1251099A/en active Pending
- 1998-01-23 EA EA199900692A patent/EA199900692A1/en unknown
- 1998-01-23 IL IL13113098A patent/IL131130A0/en unknown
- 1998-01-23 SK SK1000-99A patent/SK100099A3/en unknown
- 1998-01-23 AU AU60384/98A patent/AU728812B2/en not_active Ceased
- 1998-01-27 AR ARP980100357A patent/AR011092A1/en unknown
- 1998-01-28 PE PE1998000064A patent/PE52299A1/en not_active Application Discontinuation
- 1998-01-28 HR HR9705041.3A patent/HRP980044A2/en not_active Application Discontinuation
-
1999
- 1999-07-23 IS IS5131A patent/IS5131A/en unknown
- 1999-07-27 NO NO993646A patent/NO993646L/en not_active Application Discontinuation
- 1999-08-24 BG BG103686A patent/BG103686A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL131130A0 (en) | 2001-01-28 |
ID22273A (en) | 1999-09-23 |
HUP0002053A2 (en) | 2001-08-28 |
CA2278739A1 (en) | 1998-07-30 |
WO1998032753A1 (en) | 1998-07-30 |
PL334833A1 (en) | 2000-03-27 |
JP2001509166A (en) | 2001-07-10 |
TR199902442T2 (en) | 2000-07-21 |
EA199900692A1 (en) | 2000-02-28 |
NO993646L (en) | 1999-09-27 |
HRP980044A2 (en) | 1998-10-31 |
PE52299A1 (en) | 1999-05-26 |
BG103686A (en) | 2000-06-30 |
CN1251099A (en) | 2000-04-19 |
SK100099A3 (en) | 2000-05-16 |
AR011092A1 (en) | 2000-08-02 |
AU6038498A (en) | 1998-08-18 |
EP0968209A1 (en) | 2000-01-05 |
AU728812B2 (en) | 2001-01-18 |
BR9807096A (en) | 2000-04-18 |
KR20000070568A (en) | 2000-11-25 |
HUP0002053A3 (en) | 2001-09-28 |
IS5131A (en) | 1999-07-23 |
EE9900328A (en) | 2000-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO993646D0 (en) | Thiazole benzenesulfonamides as <beta> 3 agonists for the treatment of diabetes and obesity | |
NO964548D0 (en) | Substituted sulfonamides as selective 3 agonists for the treatment of diabetes and obesity | |
NO20006630D0 (en) | Pharmaceutical composition for the treatment of diabetes | |
AU3723297A (en) | Substituted sulfonamides as selective beta3 agonists for the treatment of diabetes and obesity | |
GB9619331D0 (en) | Selective ›3 agonists for the treatment of diabetes and obesity | |
DZ2936A1 (en) | New modified release composition for the treatment of diabetes. | |
NO976063D0 (en) | Procedure for the treatment of diabetes | |
NO308131B1 (en) | Hypolipidemic 1,4-benzothiazepine-1,1-dioxides, their use and pharmaceutical composition | |
DK1206457T3 (en) | Biaryl-oxa (thia) zole derivatives and their use as modulators PPAPs | |
NO961432D0 (en) | Benzophiophenes and related compounds as estrogen agonists | |
DK0996444T3 (en) | Treatment of diabetes with thiazolidinedione and metformin | |
AU3374897A (en) | Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity | |
ZA953336B (en) | Substituted sulfonamides as selective B3 agonists for the treatment of diabetes and obesity | |
NO972451D0 (en) | 2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and preparations and process for use thereof | |
NO20001914D0 (en) | <alfa> -Aryl-N-alkylnitrons and pharmaceutical compositions containing them | |
HUP0003876A3 (en) | Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes | |
NO20022087D0 (en) | Procedure for the treatment of diabetes | |
ZA98647B (en) | Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity | |
IT1294080B1 (en) | PROCEDURE AND APPARATUS FOR THE EXTERNAL INSPECTION OF CONTAINERS. | |
DE69432116D1 (en) | Ceramic composition and thermistor containing this ceramic composition | |
FI941776A0 (en) | Process for the preparation of 1,2,4-thiadiazoles | |
DE69610602D1 (en) | Antiferroelectric liquid crystal compound and antiferroelectric liquid crystal composition | |
NO996467D0 (en) | Process for the preparation of thiazofurine and other C-nucleosides | |
NO20000229D0 (en) | Treatment of diabetes with thiazolidinedione and sulfonylurea | |
NO996264D0 (en) | Treatment of diabetes with thiazolidinedione and sulfonylurea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |